Day One Biopharmaceuticals (DAWN) EBIAT (2022 - 2025)
Day One Biopharmaceuticals (DAWN) has disclosed EBIAT for 4 consecutive years, with -$21.3 million as the latest value for Q4 2025.
- On a quarterly basis, EBIAT rose 67.62% to -$21.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$107.3 million, a 12.38% decrease, with the full-year FY2025 number at -$107.3 million, down 12.38% from a year prior.
- EBIAT was -$21.3 million for Q4 2025 at Day One Biopharmaceuticals, down from -$19.7 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $37.0 million in Q3 2024 to a low of -$65.7 million in Q4 2024.
- A 4-year average of -$33.4 million and a median of -$37.2 million in 2022 define the central range for EBIAT.
- Peak YoY movement for EBIAT: skyrocketed 180.25% in 2024, then crashed 588.04% in 2025.
- Day One Biopharmaceuticals' EBIAT stood at -$40.1 million in 2022, then tumbled by 35.91% to -$54.5 million in 2023, then dropped by 20.55% to -$65.7 million in 2024, then soared by 67.62% to -$21.3 million in 2025.
- Per Business Quant, the three most recent readings for DAWN's EBIAT are -$21.3 million (Q4 2025), -$19.7 million (Q3 2025), and -$30.3 million (Q2 2025).